You are on page 1of 3

Piramal Phytocare Share Price Breached Upper Circuit

Piramal Phytocare share price


surged up by a massive 19.99 per
cent in the Mondays trading
session to breach the upper circuit.
Todays High lights
Spurt in Volume by more
than 6.92 times
Breached Upper Circuit Rs.
100.10
The Fundamentals at a Glance
Exchange Symbol
Sector
Current Price * (Rs.)
Face Value (Rs.)
52 Week High (Rs.)
52 Week Low (Rs.)
Life Time high (Rs.)
Life Time low (Rs.)
Average Daily Movement [ADM]
Average Volume [20 days]
1 Month Return (%)
Consolidated FY 15-16 PE Ratio
Consolidated Trailing PE Ratio
Standalone FY 15-16 PE Ratio
Standalone Trailing PE Ratio
Book Value
Market Cap
% of Promoter holding pledged

PIRPHYTO (NSE)
PHARMA
99.65
10
140.60 (28-Dec-15)
47.10 (29-Feb-16)
519.00 (29-May-08)
3.10 (23-Dec-11)
6.28
33460
-20.6
0
0
0
0
1.92
215.60 (Cr)
0

Piramal Phytocare as a top 500 stock


Piramal Phytocare is one of the top 500 Shares identified by Dynamic research team at
the end of every quarter out of 1700 plus Shares on the National Stock Exchange.
Piramal Phytocare has strong fundamentals. Strong Fundamentals mean Piramal
Phytocare has not made any losses in last 2 quarters, debt equity is less than 2 (not
applicable for NBFC and banks) and pledge is less than 25 per cent. These top 500
Shares are safe for investment.
Dynamic levels research experts provide Piramal Phytocare share price target along
with share market tips for the stock with the help of our unique research tools (the
ladder). These tips are updated every day, please check this page daily for new tips
(visit Piramal Phytocare share price target). Sometimes the entry rate may be very far
from the previous day close.
The investors need to be patient, as entry at these levels will have a strong probability
to give better results.
The Important Levels
Piramal Phytocare broke the closest resistance levels by rising massively today. Get
the most important support and resistance levels of the share at Piramal Phytocare
share price forecast.
About Piramal Phytocare
The Piramal Group is a diversified conglomerate with operations spread in more than
30 countries and with brand-presence across 100 markets around the world. Since the
late 1980s, the Piramal Group has evolved from a textile-centric business to a
diversified pharmaceutical-based global organization. The Piramal Group operates
across sectors like healthcare, life sciences, drug discovery, healthcare information
management, financial services, specialty glass packaging and real estate.
As a Group the company consistently identified opportunities ahead of the curve, even
when market situations suggest the opposite. The company invested in the domestic
formulations business when others were focused on growing international generics.
This persistence paid off when a deal with Abbott in 2010 valued our business at USD
3.72 billion, an unprecedented 9x sales and 30x EBITDA.

Disclaimer
The investment advice or guidance provided by way of recommendations, reports or other ways are solely the personal views of the research
team. Users are advised to use the data for the purpose of information and rely on their own judgment while making investment decision.
Dynamic Equities Pvt. Ltd - SEBI Investment Advisory Reg. No.: INA300002022

Disclosure
Dynamic Equities Pvt. Ltd. is a member of NSE, BSE, MCX SX and a DP with NSDL & CDSL. It is also engaged in Investment Advisory
Services and Portfolio Management Services. Dynamic Commodities Pvt. Ltd., associate company, is a member of MCX & NCDEX. We
declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered.
SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise letters or levied
minor penalty on for certain operational deviations.
Answers to the Best of our knowledge and belief of Dynamic/ its Associates/ Research Analyst: DYNAMIC/its Associates/ Research Analyst/
his Relative:
Do not have any financial interest / any actual/beneficial ownership in the subject company.
Do not have any other material conflict of interest at the time of publication of the research report
Have not received any compensation from the subject company in the past twelve months
Have not managed or co-managed public offering of securities for the subject company.
Have not received any compensation for brokerage services or any products / services or any compensation or other benefits from the
subject company, nor engaged in market making activity for the subject company
Have not served as an officer, director or employee of the subject company

Article Written by
Nabarupa Kanjilal